Development and Validation of a Method for Quantitative Determination of Innovative Antitumor Peptide Drugs in Order to Study their Pharmacokinetics

According to the World Health Organization (WHO), oncological diseases hold second place in the world in terms of mortality after cardiovascular diseases; and in the next few decades the number of cases will continue to increase [1]. Development of medicines based on modified endogenous peptides is one of the most relevant areas of modern medicine. The most interesting among them are antitumor peptide drugs, which are no less effective than chemotherapy with its pronounced side effects, or surgical interventions that often take a toll on patients [2]. When conducting studies of peptide preparations in biological fluids, the structure of the peptide molecule and its physicochemical properties are taken into account.